Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Staphylococcal Vaccine

Conditions

Staphylococcal Vaccine

Trial Timeline

Jul 2, 2015 → Jun 27, 2019

NCT ID

NCT02388165

About Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine

Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine is a phase 2 stage product being developed by Pfizer for Staphylococcal Vaccine. The current trial status is terminated. This product is registered under clinical trial identifier NCT02388165. Target conditions include Staphylococcal Vaccine.

What happened to similar drugs?

4 of 5 similar drugs in Staphylococcal Vaccine were approved

Approved (4) Terminated (2) Active (1)

✅Daptomycin + VancomycinMerckApproved

🔄Daptomycin 4 mg/kg + Comparator: vancomycin + Daptomycin 6 mg/kgMerckPhase 3

✅Daptomycin + VancomycinMerckApproved

✅DaptomycinNovartisApproved

✅TigecyclinePfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02388165	Phase 2	Terminated	Jul 2, 2015	Jun 27, 2019	Staphylococcal Vaccine

Competing Products

20 competing products in Staphylococcal Vaccine

See all competitors

Product	Company	Stage	Hype Score
Ceftobiprole	Johnson & Johnson	Phase 1	29
Ceftobiprole	Johnson & Johnson	Phase 1	29
Daptomycin + Vancomycin	Merck	Approved	35
Daptomycin 4 mg/kg + Comparator: vancomycin + Daptomycin 6 mg/kg	Merck	Phase 3	40
V710 + Placebo	Merck	Phase 1	29
V710 + Comparator: Placebo	Merck	Phase 1	29
V710 (30 µg) with MAA + V710 (30 µg) without MAA	Merck	Phase 1	29
Daptomycin + Vancomycin	Merck	Approved	43
Daptomycin	Novartis	Approved	35
SA4Ag vaccine	Pfizer	Phase 1	29
linezolid (Zyvox)	Pfizer	Pre-clinical	26
Staphylococcus aureus 4-antigen vaccine + Placebo	Pfizer	Phase 2	35
Tigecycline	Pfizer	Approved	43
SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + Placebo	Pfizer	Phase 1	29
SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + SA3Ag vaccine + Placebo	Pfizer	Phase 1	29
NDV-3 vaccine with alum IM + NDV-3 vaccine without alum IM + Placebo with alum IM + NDV-3 vaccine without alum ID	United Therapeutics	Phase 1	26
NDV-3 investigational vaccine	United Therapeutics	Phase 1	26
TD-1792 + Vancomycin	Theravance Biopharma	Phase 2	29
Ceftobiprole	Basilea Pharmaceutica	Phase 1	23
human lactoferrin peptide 1-11	AM-Pharma	Phase 1/2	14